BORTEZOMIB 3.5 MG
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG · DIN 02456176 · APOTEX INC
Health Canada status: MARKETED
What is BORTEZOMIB?
BORTEZOMIB 3.5 MG contains BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02456176, held by APOTEX INC, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 25-Mar-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BORTEZOMIB used for?
BORTEZOMIB (bortezomib for Injection) is indicated as part of combination therapy for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation; as part of a medically recognized combination therapy for induction treatment of patients with previously untreated multiple myeloma who are suitable for stem cell transplantation; for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for stem cell transplantation; as part of combination therapy for the treatment of patients with previously untreated mantle cell lymphoma who are unsuitable for stem cell transplantation; and for the treatment of patients with mantle cell lymphoma who have relapsed or were refractory to at least 1 prior therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02456176 |
|---|---|
| Brand name | BORTEZOMIB |
| Generic / active ingredient | BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) : 3.5 MG |
| Manufacturer | APOTEX INC |
| Strength | 3.5 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01XG01 BORTEZOMIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Mar-2019 |
How is it stored and handled?
When reconstituted as directed, BORTEZOMIB may be stored at 25°C. Reconstituted BORTEZOMIB should be administered within eight hours of preparation. The reconstituted material may be stored for up to eight hours in the original vial or in a syringe. The total storage time for the reconstituted material must not exceed eight hours when exposed to normal indoor lighting.
How is it supplied?
null
Is BORTEZOMIB in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01XG01 BORTEZOMIB. 12 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02438399 |
| BORTEZOMIB FOR INJECTION | 2.5 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02467003 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02493306 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02485257 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02423405 |
| BORTEZOMIB FOR INJECTION | 3.5 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02452456 |
| BORTEZOMIB INJECTION | 2.5 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02550075 |
| PMS-BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02466708 |
| TARO-BORTEZOMIB | 2.5 MG | POWDER FOR SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02511932 |
| TARO-BORTEZOMIB | 3.5 MG | POWDER FOR SOLUTION | TARO PHARMACEUTICALS INC | MARKETED | DIN 02499061 |
Who else supplies BORTEZOMIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BORTEZOMIB appears in 218 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.